Drug Trial Radar · NCT03022097
Study to Assess Efficacy and Safety of Aclidinium Bromide and Aclidinium Bromide/Formoterol Fumarate in Stabile COPD Patients
Last checked: Nov 19, 2026Latest source record: Mar 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,625
Actual
Start
Feb 2, 2017
Primary completion
Apr 14, 2022
Study completion Apr 14, 2022
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Parexel
- First posted
- Jan 16, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multiple dose, randomised, parallel, double blind, double dummy, multicentre and multinational Phase III study to determine the efficacy and safety of Aclidinium bromide/Formoterol fumarate compared with individual components and placebo and Aclidinium bromide compared with Placebo when administered to patients with stable Chronic Obstructive Pulmonary Disease (COPD).
Conditions
- COPD
Interventions
Aclidinium bromide/formoterol Fixed-Dose CombinationDrug
Inhaled Aclidinium bromide/formoterol Fixed-Dose Combination, twice per day via Genuair
Aclidinium bromideDrug
Inhaled Aclidinium bromide 400 μg, twice per day via Genuair
Formoterol FumarateDrug
Inhaled Formoterol Fumarate 12 μg, twice per day via Turbuhaler
PlaceboDrug
Inhaled dose-matched placebo, twice per day via Genuair or via Turbuhaler
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in 1-hour Morning Post Forced Expiratory Volume in 1 Second (FEV1)Time frame: Week 24, 1-hour morning post-dose
- Change From Baseline in Morning Pre-dose (Trough) FEV1 for Aclidinium Bromide/Formoterol FumarateTime frame: Week 24, morning pre-dose (trough)
- Change From Baseline in Morning Pre-dose (Trough) FEV1 for Aclidinium BromideTime frame: Week 24, morning pre-dose (trough)
Locations
74 sites in 5 countries. Site status is shown where the registry gives one.
Research Site
Baotou, China
Research Site
Beijing, China
Research Site
Beijing, China
Research Site
Beijing, China
Research Site
Beijing, China
Research Site
Cangzhou, China
Research Site
Changchun, China
Research Site
Changsha, China
Research Site
Changsha, China
Research Site
Chengdu, China
Research Site
Guangzhou, China
Research Site
Haikou, China
Research Site
Hangzhou, China
Research Site
Hangzhou, China
Research Site
Hangzhou, China
Research Site
Hefei, China
Research Site
Hefei, China
Research Site
Hefei, China
Research Site
Hengyang, China
Research Site
Hohhot, China
Research Site
Liangyugang, China
Research Site
Linhai, China
Research Site
Nanchang, China
Research Site
Nanjing, China
Research Site
Qiqihar, China
Research Site
Shanghai, China
Research Site
Shanghai, China
Research Site
Shanghai, China
Research Site
Shanghai, China
Research Site
Shanghai, China
Research Site
Shanghai, China
Research Site
Shanghai, China
Research Site
Shanxi, China
Research Site
Shengyang, China
Research Site
Shenzhen, China
Research Site
Shenzhen, China
Research Site
Shijiazhuang, China
Research Site
Taiyuan, China
Research Site
Tianjin, China
Research Site
Wenzhou, China
Showing 40 of 74 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.